Anti-CTLA-4 therapy results in higher CD4(+)ICOS(hi) T cell frequency and IFN-γ levels in both nonmalignant and malignant prostate tissues

Cytotoxic lymphocyte antigen-4 (CTLA-4) blockade is an active immunotherapeutic strategy that is currently in clinical trials in cancer. There are several ongoing trials of anti-CTLA-4 in the metastatic setting of prostate cancer patients with reported clinical responses consisting of decreases in t...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Chen, Hong, Liakou, Chrysoula I., Kamat, Ashish, Pettaway, Curtis, Ward, John F., Tang, Derek Ng, Sun, Jingjing, Jungbluth, Achim A., Troncoso, Patricia, Logothetis, Christopher, Sharma, Padmanee
Formato: Artigo
Lenguaje:Inglês
Publicado: National Academy of Sciences 2009
Materias:
Biological Sciences
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC2650334/
https://ncbi.nlm.nih.gov/pubmed/19202079
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.0813175106
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares